certolizumab pegol

Ligand id: 6774

Name: certolizumab pegol

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: certolizumab pegol

No information available.
Summary of Clinical Use
Used to treat rheumatoid arthritis and Crohn's disease [1]. May also have some effect in related conditions such as axial spondyloarthritis [3]. The EMA refused Europe-wide approval for the use of this drug, but individual nations have granted approval for its use (e.g. the UK in 2009).
Mechanism Of Action and Pharmacodynamic Effects
A recombinant Fab' antibody fragment/40kDa polyethylene glycol (PEG2MAL40K) conjugate against TNFα. By neutralising TNFα (soluble and membrane forms), certolizumab pegol disrupts production of pro-inflammatory cytokines such as IL-1β, and this may account for its effectiveness in treating autoimmune conditions such as Crohn's disease [2] and rheumatoid arthritis.
External links